Durvalumab antibody | AbD41327
A microtiter plate was coated overnight with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST + 5% BSA, Human Anti-Durvalumab Antibody, clone AbD41327ad (TZA004) at a concentration of 2 μg/ml was added. Detection was performed using HRP conjugated anti-DYKDDDDK tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit (LNK002P).
A microtiter plate was coated overnight with durvalumab, human PD-L1, human IgG1 kappa isotype control or human Fab VH3-23/κ3 control at a concentration of 5 µg/ml. After washing and blocking with PBST + 5% BSA, detection was performed using Human Anti-Durvalumab Antibody, clone AbD41327ad (TZA004) titrated to the given concentrations in PBST, followed by an HRP conjugated anti-DYKDDDDK tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with Human Anti-Durvalumab Antibody, clone AbD41327ad (TZA004) at a concentration of 1 µg/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of durvalumab. Detection was performed using HRP conjugated Human Anti-Durvalumab Antibody, clone AbD41313ia (HCA360) at a concentration of 0.5 µg/ml in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit (LNK002P).
A microtiter plate was coated overnight with human PD-L1 at a concentration of 1 µg/ml. After washing and blocking with PBST + 5% BSA, a pre-incubated mixture of durvalumab (0.15 µg/ml) plus increasing concentrations of Human Anti-Durvalumab Antibody, clone AbD41327ad (TZA004, inhibitory) or clone AbD41238ad (non-inhibitory control) was added. Both antibodies were in the monovalent Fab fragment format. Free durvalumab, still capable of binding to the human PD-L1 coated plate, was detected using HRP conjugated Mouse anti Human Fc specific Antibody (MCA647P) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Filter by Application:
E ResetHuman anti Durvalumab
- Product Type
- Monoclonal Antibody
- Clone
- AbD41327
- Isotype
- Fab antibody
- Specificity
- Durvalumab
TZA004
| Human Anti-Durvalumab Antibody, clone AbD41327ad is a paratope specific, inhibitory anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug durvalumab. The antibody does not recognize free PD-L1 nor durvalumab in complex with PD-L1. Anti-Durvalumab monovalent Fab antibody TZA004 has a SpyTag incorporated for conversion by the user into alternative antibody formats using any of the SpyCatchers available in our catalog. View a summary of all SpyCatcher products Anti-Durvalumab monovalent Fab antibody TZA004 may be used as the capture antibody for durvalumab in a PK bridging ELISA together with HCA360, clone AbD41313ia as the detection antibody to measure free durvalumab captured via immobilized PD-L1. PK bridging ELISA Durvalumab (Imfinzi) is a human IgG1/kappa antibody with allotype G1m3. The CH2 domain was engineered with three amino acid substitutions (L238F, L239E, P335S) to reduce the Fc-mediated effector functions to prevent depletion of PD-L1+ T-cells. It was first approved for previously treated patients with advanced bladder cancer. It was later approved for the treatment of unresectable stage 3 NSCLC (Non-Small Cell Lung Cancer) and ES-SCLC. Durvalumab binds to PD-L1 to block the interaction with the inhibitory T cell receptor PD-1. This blockade removes the suppression of T-cells that are specific for MHC-1-presented neoepitopes on tumor cells. Removal of this inhibitory signal leads to the release of granzymes and perforins by the activated T-cells, and finally to the destruction of the tumor cells. View a summary of all anti-durvalumab antibodies |
- Target Species
- Drug
- Product Form
- A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL® phage display library, expressed in a proprietary E. coli strain. The antibody is tagged with a DYKDDDDK tag, a SpyTag version 2 (VPTIVMVDAYKRYK) and a His6-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.
- Preparation
- Metal chelate affinity chromatography
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.0095% MIT
- Immunogen
- Durvalumab
- Affinity
- The monovalent intrinsic affinity of AbD41327ad was measured as KD = 3.6 nM by real time, label free molecular interaction analysis on immobilized durvalumab.
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
- ELISA Matched Pair(s)
-
ELISA Matched Pair-Detection Antibody:
HCA360
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
His-tag is a registered trademark of EMD Biosciences.
Imfinzi is a registered trademark of Medimmune/AstraZeneca using Abgenix's XenoMouse technology.
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols for coupling a Fab antibody with a SpyTag to a SpyCatcher can be found at SpyTag and SpyCatcher Products, and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- Clone AbD41327ad can be used as the capture antibody for durvalumab in a PK ELISA together with HCA360 as the detection antibody.
PK bridging ELISA
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | LYNX Rapid HRP Antibody Conjugation Kit | ||||||
| SpyTag3 Peptide | BLP086 | IY | 1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | SpyTag3 Peptide | ||||||
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Hispec Assay Diluent | ||||||
| Human anti Durvalumab | HCA359 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Durvalumab | ||||||
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
TZA004
163204
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with Durvalumab specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
View all Anti-Drug ProductsAlways be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up